[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intrauterine-growth-restriction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intrauterine-growth-restriction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,71,96,124,143,170,195,223,245,270,295],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100389856","phase-3-chronic-hypertension-and-acetyl-salicylic-acid-in-pregnancy-100389856",false,"NCT04356326","Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy","Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a Multicenter Prospective Randomized Double-blind Placebo-controlled Trial.","CHASAP","Inclusion Criteria:\n\n* Pregnant patient between 10 and 19 weeks of gestation + 6 days\n* Chronic hypertension, whether treated or not, know before pregnancy or diagnosed before randomization\n* Singleton pregnancy\n* Signed the written informed consent\n* Affiliation to social security\n\nExclusion Criteria:\n\n* ---Medical history requiring anticoagulation (antiphospholipid syndrome, deep vein thromboembolic disease, pulmonary embolism, atherothrombosis, patient with mechanical heart valves),\n* Patient receiving aspirin for another indication outside pregnancy,\n* Patient with significant proteinuria (\\> 300mg\u002F24 hours or a proteinuria\u002Fcreatininuria ratio ≥ 30mg\u002Fmmol),\n* Active bleeding,\n* History of severe PE with delivery \\\u003C 34 weeks of gestation,\n* Hypersensitivity to salicylates such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs),\n* Platelet count lower than 100,000 cells\u002Fmicroliter (dosage less than 6 months old),\n* Hemostasis disorders, including hemophilia (with thrombocytopenia)\n* Any constitutional or acquired hemorrhagic disease, (including digestive hemorrhages, history of hemorrhagic stroke and thrombocytopenia\n* Human immunodeficiency virus, or hepatitis B virus, or hepatitis C virus positive serum,\n* Patient included in another interventional study which could interfere with the results of the study,\n* Age \\\u003C18 years old,\n* Women under the protection of justice,\n* Patients with psychiatric follow-up, poor understanding of French or cognitive problems,\n* Duodenal ulcer,\n* Severe renal impairment,\n* Severe hepatic insufficiency,\n* Severe cardiac impairment,\n* Gout,\n* Patients with known glucose-6-phosphate dehydrogenase deficiency,","FEMALE","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A randomized clinical trial to assess the efficiency of acetylsalicylic acid (aspirin) 150 mg\u002Fday started before 20 weeks of gestation in the prevention on maternal and fœtal complications in pregnant women with chronic hypertension.",[27,28,29,30,31,32],"Chronic Hypertension Complicating Pregnancy","Pre-Eclampsia","Intrauterine Growth Restriction","Aspirin","Perinatal Death","Placental Abruption","RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-12","ACTUAL",{"date":39,"type":37},"2021-02-15",{"date":41,"type":21},"2030-02",{"name":43,"class":44},"Centre Hospitalier Intercommunal Creteil","OTHER",20,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100616946","a-prospective-longitudinal-observational-cohort-study-of-pregnant-women-residing-at-high-altitude-in-bolivia-100616946","NCT07312227","A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia","Inclusion Criteria:\n\n* women delivering at participating hospitals at more than 3500 meters or women delivering at participating hospitals at sea level\n* signed informed consent\n\nExclusion Criteria:\n\n* preexisting cardiopulmonary pathologies (CHD, COPD, CKD, NYHA \\> III)",true,"45 Years",{"count":55,"type":21},27,"OBSERVATIONAL","In this study, the investigators will follow two small cohorts of pregnant women: a cohort of healthy women with uncomplicated pregnancies residing at high altitude, a control group of healthy women with uncomplicated pregnancies residing at sea level, to characterize differences in cardiopulmonary adaptation and nitric oxide (NO) pathway expression at elevations \\>3,500 m throughout pregnancy and into the postpartum period. The investigators aim to investigate right-sided cardiac impairment induced by chronic hypobaric hypoxemia, its effects on fetal growth, and the potential contribution of cardiovascular nitric oxide depletion to obstetric complications.",[59,60,29],"Hypertensive Disorder of Pregnancy","Pulmonary Arterial Hypertension","2026-05-21",{"date":63,"type":37},"2026-05-26",{"date":65,"type":37},"2026-02-11",{"date":67,"type":21},"2027-02",{"name":69,"class":44},"Massachusetts General Hospital",2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100628480","impact-of-enoxaparin-therapy-on-fetal-outcomes-in-intrauterine-growth-restriction-100628480","NCT07462182","Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction","Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction With Oligohydramnios.","Inclusion Criteria:\n\n* Women aged 18-40 years\n* Singleton pregnancy\n* Gestational age ≥28 weeks (confirmed by first-trimester scan or reliable last menstrual period)\n* Diagnosed with both IUGR and oligohydramnios\n* Willing to provide informed written consent\n\nExclusion Criteria:\n\n* Multiple gestation\n* Major fetal congenital anomalies\n* Maternal medical disorders affecting pregnancy outcome (e.g., uncontrolled diabetes, chronic hypertension, renal disease)\n* Known coagulation disorders or contraindications to enoxaparin\n* Women already on anticoagulation therapy.","40 Years",{"count":80,"type":21},108,[82],"NA","The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.",[29],"NOT_YET_RECRUITING","2026-03-04",{"date":88,"type":37},"2026-03-10",{"date":90,"type":21},"2026-04-01",{"date":92,"type":21},"2026-09-30",{"name":94,"class":44},"Muhammad Aamir Latif",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":52,"sex":17,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":95},"100336573","investigating-the-structured-use-of-ultrasound-scanning-for-fetal-growth-100336573","NCT03662178","Investigating the Structured Use of Ultrasound Scanning for Fetal Growth","Investigating the Structured Use of Ultrasound Scanning for Fetal Growth (Oxford Growth Restriction Identification Programme (OxGRIP)) on Risk Factors for and the Incidences of Adverse Maternal, Fetal and Neonatal Outcome","OxGRIP","Inclusion Criteria:\n\n• All pregnant women receiving antenatal care at the Oxford University Hospitals NHS Foundation Trust (OUHFT) from January 2013 to 31st December 2019 with no exclusion criteria\n\nExclusion Criteria:\n\n* Women who have opted out of research related to pregnancy in this pregnancy whilst receiving care by the OUHFT.\n* If intrapartum care takes place outside of the OUHFT.","16 Years","60 Years",{"count":107,"type":21},56000,"Fetal growth restriction during pregnancy represents one of the biggest risk factors for stillbirth (Gardosi et al, 2013), with 'about one in three term, normally formed antepartum stillbirths are related to abnormalities of fetal growth' (MBRRACE, 2015).\n\nTherefore, antenatal detection of growth restricted babies is vital in order to be able to monitor and decide the appropriate delivery timing.\n\nHowever, antenatal detection of SGA babies has been poor, varying greatly across trusts in England in those that calculate their rates (NHS England, 2016). Most trusts do not calculate their detection rates and rates are therefore unknown. It is estimated that routine NHS care detects only 1 in 4 growth restricted babies (Smith, 2015).\n\nOxford University Hospitals NHS Foundation Trust, in partnership with the Oxford Academic Health Science Network (AHSN) has introduced a clinical care pathway (the Oxford Growth Restriction Pathway (OxGRIP)) designed to increase the rates of detection of these at risk babies. The pathway is intended to increase the identification of babies who are at risk of stillbirth, in order to try to prevent this outcome, whilst making best usage of resources, and restricting inequitable practice and unnecessary obstetric intervention.\n\nIt has been developed with reference to a body of research, however, the individual parts of care provided have not been put together in a pathway in this manner before. Therefore it is important to examine whether the pathway meets its goals of improving outcomes for babies in a 'real world' setting.\n\nThe principles of the pathway are\n\n1. A universal routine scan at 36 weeks gestation.\n2. Additional growth scans at 28 and 32 weeks gestation based on a simplified assessment of risk factors and universal uterine artery Doppler at 20 weeks gestation.\n3. Assessment of further parameters other than estimated fetal weight associated with adverse perinatal outcome (eg growth velocity, umbilical artery Doppler and CPR).\n\nThe clinical data routinely collected as a result of the introduction of the pathway offers a valuable and unique resource in identifying and analysing in the effects of the pathway on its intended outcomes and also in investigating and analysing other maternal, fetal and neonatal complications and outcomes, establishing normal \u002F reference ranges for ultrasound values.",[110,111,112,113,114,31,29],"Stillbirth","Fetal Death","Fetal Growth Retardation","Small for Gestational Age","Fetal Growth Restriction","2026-01-27",{"date":117,"type":37},"2026-01-29",{"date":119,"type":37},"2017-09-01",{"date":121,"type":21},"2029-09-30",{"name":123,"class":44},"Oxford University Hospitals NHS Trust",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":130,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":70},"100231982","mri-assessment-of-placental-health-100231982","NCT02297724","MRI Assessment of Placental Health","Inclusion Criteria:\n\n1. The pregnant mother with twin gestation with diagnosis of selective IUGR based upon obstetrical US findings as following:\n\n   * Proven monochorionicity \u002F dichorionicity\n   * Discordance in estimated fetal weight (EFW). Growth restriction (\\\u003C10 percentile of norm) in one or both fetus(es) AND\u002FOR growth discordance (\\> or = 20%) between twin fetuses.\n2. The pregnant mother with singleton gestation with diagnosis of IUGR based upon obstetrical US findings as following:\n\n   * Proven singleton gestation\n   * Growth restriction of fetus (\\\u003C10 percentile of norm)\n   * Doppler measurements that indicates placental insufficiency: umbilical artery, middle cerebral artery, uterine artery; or oligohydramnios.\n3. Gestational age: Bigger than 18 weeks.\n4. Pregnant mother is between age 18 to 45, clinically stable and can safely tolerate fetal MRI study.\n\nExclusion Criteria:\n\nFetuses\u002Finfants with the following features will be excluded.\n\n1. Fetus\u002Finfant with chromosomal anomalies or known genetic disorders.\n2. Fetus\u002Finfant with other major congenital malformation.\n3. Presence of any condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient, quality or completeness of the data.\n\nPregnant mothers with the following features will be excluded.\n\n1. Mothers with contraindication to MRI (with pacemaker, metal in body, oversize).\n2. Mothers with claustrophobia\n3. Mothers medically unstable for the MRI study",{"count":131,"type":21},80,"The ultimate goal of this project is to develop methods that allow informed decision-making on the delivery time of fetuses that are at increased risk of stillbirth due to IUGR. In placenta related IUGR pregnancies, there can be multiple concurrent placental pathologies. Although there is no specific correspondence between a single type of pathology and IUGR, the common result of these pathologies is placental insufficiency, which limits the maternal-fetal exchange. Oxygen and nutrition transport is known to be hindered in IUGR placentas due to obstructed or abrupt vasculature, massive fibrin deposition, and inflammation in the villous and intervillous space (villitis). Thus one potential approach to distinguish IUGR pregnancies from normal ones is to assess the efficiency of placental transport. Based on the hypothesis that efficiency of oxygen transport is representative for overall oxygen and nutrition transport in placenta, the investigators propose to characterize the blood oxygenation and blood perfusion in placenta in vivo via MRI, and use it as an index for better stratification in the IUGR risk group. The investigators will also consider alternative MRI approaches such as structural, diffusion and spectroscopy measurements inside the placenta, which might reflect the state of placental transport and reveal the status of placental health.\n\nSpecific aims: 1) To correlate the MRI metrics that differentiate placental insufficiency from normal placenta transport with histopathology data of the placenta. 2) To correlate the MRI metrics that reflects placental insufficiency with fetal outcome",[29],"2025-12-09",{"date":136,"type":37},"2025-12-12",{"date":138,"type":4},"2014-04",{"date":140,"type":21},"2028-09",{"name":142,"class":44},"Boston Children's Hospital",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":150,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":95},"100533456","growing-little-peapods-study-100533456","NCT06226051","Growing Little PEAPODS Study","Growing Little PEAPODS Study: Association Between Prematurity and Body Composition, Nutrition Practices, and Neurodevelopmental Outcomes","Neonate Inclusion Criteria:\n\n* Born inpatient at Meriter Hospital, Inc. at or above 22 gestational weeks. Upper limit is 32 weeks 6 days GA (possible gestational age range from 22w0d-32w6d)\n\nNeonate Exclusion Criteria:\n\n* Known genetic condition that impacts neurodevelopmental outcomes or brain structure development\n* Multiple major congenital anomalies\n* Per the investigator's opinion, the subject will likely require transfer to American Family Children's Hospital (AFCH) before 36 weeks PMA\n\n  * Any neonate who enrolls in the study and then unexpectedly requires transfer to AFCH before 36 weeks PMA will be excluded from the study if they are unable to obtain at least one body composition measurement before transfer. Body composition data points can only be collected at Meriter Hospital due to the location of PEAPOD\n\nBirthing Parent Inclusion Criteria:\n\n* Birthing parent must speak English or Spanish due to consent documents\n* Able to understand and willing to sign a written informed consent document\n* Primary caregiver of a neonate who is eligible to participate in the study\n* Agrees to enroll neonate into the study\n* Willing to comply with all study procedures and be available for the duration of the study\n* Age 15 or older\n\nBirthing Parent Exclusion Criteria:\n\n* Subject is unable to provide informed consent, including subjects in foster care and subjects within state custody\n* Does not plan to maintain custody of the child after birth, such as in instances of adoption or surrogacy","ALL","22 Weeks","32 Weeks",{"count":154,"type":21},120,"The goal of this clinical trial is to learn more about how the food and nutrition babies receive while in the Neonatal Intensive Care Unit (NICU) influences their ability to gain weight and fat-free mass, and their future growth and development.\n\nParticipants will:\n\n* have body growth measurements collected using the PEAPOD device\n* have nutritional information collected, and\n* be followed for neurodevelopmental outcomes\n\nParticipants can expect to be in the study for 36 months.",[157,158,159,29,160],"Premature Birth","Premature Infant","Premature","Small for Gestational Age at Delivery","2025-08-07",{"date":163,"type":37},"2025-08-12",{"date":165,"type":37},"2024-09-04",{"date":167,"type":21},"2028-01",{"name":169,"class":44},"University of Wisconsin, Madison",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":52,"sex":150,"minAge":4,"maxAge":4,"enrollmentInfo":177,"targetDuration":179,"studyType":56,"phases":4,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":95},"100524929","peppi-study-identification-of-women-at-risk-for-placental-dysfunction-100524929","NCT06115122","PEPPI Study: Identification of Women at Risk for Placental Dysfunction","PEPPI Study: Identification of Women at Risk for Placental Dysfunction During the First and Third Trimesters of Pregnancy","Mothers\n\nInclusion Criteria for PEPPI-study\n\n* Pregnant (first trimester)\n* Understands Finnish\n* ≥18 years\n* Signed informed consent\n\nExclusion Criteria\n\n* Multiple pregnancy\n* Miscarriage\u002Ftermination of the index pregnancy\n* No first trimester blood sampling\n\nInclusion Criteria for FERPPI-study\n\n* Participates in PEPPI-study (criteria above)\n* Blood samples at first and third trimester of pregnancy\n* Permits blood sampling from the umbilical cord when the baby is born\n\nExclusion Criteria\n\n* No first or third trimester blood sampling\n* No umbilical cord blood sample after baby is born\n\nFathers\n\nInclusion Criteria\n\n* Biological father to the child born for the mother who participated in PEPPI study\n* ≥18 years\n* Signed informed consent\n\nExclusion Criteria\n\n• Does not understand Finnish\n\nChildren\n\nInclusion Criteria for PEPPI-study\n\n* Born to mother who participated in PEPPI study\n* Signed informed consent from parent(s)\n\nExclusion Criteria\n\n• No consent from parent(s)\n\nInclusion Criteria for PEPPI-offspring study • Mother in risk-, control-, or PCOS group during PEPPI-study with ultrasound information at gestational weeks 30-32 or a mother who developed pre-eclampsia during the pregnancy regardless of their study group during PEPPI-study\n\nExclusion Criteria\n\n• Mother\u002Ffather declines participation\n\nInclusion Criteria for FERPPI-study\n\n* Signed informed consent from parent(s)\n* Mother has blood samples taken at first and third trimester (iron status)\n* Child has blood samples taken at birth and at 3 months of age\n\nExclusion Criteria\n\n* No consent from parent(s)\n* No blood samples from mother\n* No blood samples from child",{"count":178,"type":21},3000,"15 Years","The main purpose of this study is to evaluate Fetal Medicine Foundation's pre-eclampsia risk calculator using maternal characteristics, first trimester serum placental growth factor (PlGF) and mean arterial pressure (MAP) in a Finnish general population.\n\nCondition or disease: pre-eclampsia, intrauterine growth restriction, polycystic ovary syndrome",[28,29,182,183,184,59,185],"Polycystic Ovary Syndrome","Iron-deficiency","Cardiovascular Diseases","Proteinuria in Pregnancy","2025-07-31",{"date":188,"type":37},"2025-08-05",{"date":190,"type":37},"2022-02-15",{"date":192,"type":21},"2041-12-31",{"name":194,"class":44},"Oulu University Hospital",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":211,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100421367","sflt1plgf-and-planned-delivery-to-prevent-preeclampsia-at-term-100421367","NCT04766866","sFlt1\u002FPlGF and Planned Delivery to Prevent Preeclampsia at Term.","Protocol of the PE37 Study: A Multicenter Randomized Trial of Screening With sFlt1\u002FPlGF and Planned Delivery to Prevent Preeclampsia at Term","PE37","Inclusion Criteria:\n\n* Nulliparous women\n* Singleton pregnancies\n* \\>18 years old\n* 35.0-36.6 weeks of gestation\n* Maternal written consent form\n\nExclusion Criteria:\n\n* Fetuses\u002Fneonates with major malformations or genetic anomalies that could modify the timing of delivery or has an impact on obstetric outcome\n* Suspected fetal growth restriction (estimated fetal weight \\\u003C3 centile or between the 3rd and 10th centile together with abnormal Doppler in the mean uterine artery Doppler pulsatility index, or in umbilical artery pulsatility index or in the middle cerebral artery or in the cerebral umbilical index (CPR))\n* Participation in another interventional study that could modify the timing of delivery.",{"count":204,"type":21},9132,[82],"* Preeclampsia (PE) affects \\~5% of pregnancies. Although improved obstetrical care has significantly diminished associated maternal mortality, PE remains a leading cause of maternal morbidity and mortality in the world.\n* Term PE accounts for 70% of all PE and a large proportion of maternal-fetal morbidity related with this condition. Prediction and prevention of term PE remains unsolved.\n* Previously proposed approaches are based on combined screening and\u002For prophylactic drugs, but these policies are unlikely to be implementable in many world settings.\n* Recent evidence shows that sFlt1-PlGF ratio at 35-37w predicts term PE with 80% detection rate.\n* Likewise, recent studies demonstrate that induction of labor (IOL) from 37w is safe.\n* The investigators hypothesize that a single-step universal screening for term PE based on sFlt1\u002FPlGF ratio at 35-37w followed by IOL from 37w would reduce the prevalence of term PE without increasing cesarean section rates or adverse neonatal outcomes.\n* The investigators propose a randomized clinical trial to evaluate the impact of a screening of term PE with sFlt-1\u002FPlGF ratio in asymptomatic nulliparous women at 35-37w. Women will be assigned to revealed (sFlt-1\u002FPlGF known to clinicians) versus concealed (unknown) arms. A cutoff of \\>90th centile will be used to define high risk of PE and offer IOL from 37w.\n* If successful, the results of this trial will provide evidence to support a simple universal screening strategy reducing the prevalence of term PE, which could be applicable in most healthcare settings and have enormous implications on perinatal outcomes and public health policies worldwide.",[208,29,209,210,31],"Preeclampsia","Maternal Hypertension","Neonatal Outcome",[212],"Preeclampsia, angiogenic factors, perinatal death, induction of labour","2025-02-17",{"date":215,"type":37},"2025-02-19",{"date":217,"type":37},"2021-03-02",{"date":219,"type":21},"2026-12-31",{"name":221,"class":44},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",21,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":95},"100477747","placental-acute-atherosis-reflecting-subclinical-atherosclerosis-100477747","NCT05500989","PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis","PEARLS","Inclusion Criteria:\n\n* Women aged ≥ 18 years\n* Controls: Women with an uncomplicated pregnancy at the moment of inclusion (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies)\n* Cases: Women diagnosed with a preeclamptic pregnancy at the moment of inclusion\n\nExclusion Criteria:\n\n• Women who do not want to be informed about the results of the tests, or women who do not want their general practitioner and specialist(s) to be informed about the test results\n\n* Allergy or intolerance to glyceryl trinitrate, betablockers or iodinated contrast media.\n* Controls: Pre-existing chronic hypertension treated with antihypertensive medication or autoimmune disorder.",{"count":231,"type":21},226,"Pregnancy is considered a cardiovascular (CV) stress test, and complicated pregnancies are associated with an increased risk for cardiovascular disease (CVD) later in life. Moreover, it is known that often the pregnancy induced CV adaptation does not resolve completely after a short postpartum (PP) period and it is not clear whether these induced changes will resolve over a longer period of time (i.e. in the upcoming months\u002Fyears after delivery).\n\nUnderstanding the cardiac adaptation during pregnancy and the reversal process in the postpartum period, as well as the factors that influence this these processes, may provide us not only insight in this mechanism, but may help us in identifying factors that may be target points for modification.",[28,234,29,235],"HELLP Syndrome","Pregnancy","2024-12-03",{"date":238,"type":37},"2024-12-05",{"date":240,"type":37},"2016-11",{"date":242,"type":21},"2028-12",{"name":244,"class":44},"Maastricht University Medical Center",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":150,"minAge":253,"maxAge":18,"enrollmentInfo":254,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":269},"100557145","long-term-follow-up-of-children-born-in-the-petn-studies-100557145","NCT06534307","Long-term Follow-up of Children Born in the PETN Studies","Langzeiteffekt Einer Pentaerithrityltetranitrat (PETN)-Behandlung in Der Schwangerschaft - Nachbeobachtung Der Kinder Der PETN-Studien","LOOP","Inclusion Criteria:\n\n* mothers participation in one of the PETN studies\n* age above 5 years\n* completion of questionnaires for self reported data\n* written consent for physical examination\n\nExclusion Criteria - only physical examination:\n\n* physical and mental states preventing physical examination","6 Years",{"count":255,"type":21},228,"In every 10th pregnancy, the child in the uterus is insufficiently nourished, a so-called growth retardation. This occurs when the child cannot reach its growth potential due to an undersupply in the uterus. This inadequate supply is considered a developmental cause for the later development of physical diseases like cardiovascular diseases, sugar metabolism disorders and obesity as well as mental developmental problems (for example problems in cognitive skills, deficits in language development, concentration and attention).\n\nFrom 2002 to 2008, 111 patients with impaired placental blood flow were included in a small study and treated with Pentalong or placebo. From 2017 to 2022, the positive effects of the study treatment were tested on a larger number of patients. A total of 317 pregnant women were included at 14 participating study centers in Germany.\n\nIn this follow-up study, the development of the children born in the two studies will be examined. The study consists of two independent parts: firstly, questionnaires are answered by the former participants and secondly, an on-site visit is carried out to check the physical and mental health of the child.",[29,258,259],"Pentaerithrityl Teratnitrate in Pregnancy","Long-Term Effects to Children","2024-08-01",{"date":262,"type":37},"2024-08-02",{"date":264,"type":37},"2024-06-01",{"date":266,"type":21},"2028-03-31",{"name":268,"class":44},"Jena University Hospital",13,{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":278,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":294},"100442213","fetal-brain-care-therapies-for-brain-neurodevelopment-in-fetal-growth-restriction-100442213","NCT05038462","Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction","Inclusion Criteria:\n\n* Singleton pregnancies\n* Non-malformed fetus\n* Pregnancies with fetal growth restriction\n* 24-32.6 weeks of gestation\n\nExclusion Criteria:\n\n* Chromosomal or structural abnormalities diagnosed during pregnancy or in the neonatal period\n* Critical Doppler study suggesting the need for delivery within the next 14 days at the time of diagnosis: reverse end-diastolic velocity in the umbilical artery or ductus venosus pulsatility \\>95th centile\n* Maternal mental or psychiatric disorders\n* Maternal allergy to cow's milk protein",{"count":277,"type":21},304,[82],"Singleton pregnancies being diagnosed of fetal growth restriction from 24 to 32.6 weeks of gestation will be randomized to two equally sized groups: maternal oral supplementation with Lactoferrin and DHA (Docosahexaenoic acid) or placebo.",[112,29],[112,114,29,282,283,284],"Neurodevelopment","Lactoferrin","DHA","2024-03-15",{"date":287,"type":37},"2024-03-18",{"date":289,"type":37},"2023-01-18",{"date":291,"type":21},"2026-12",{"name":293,"class":44},"Institut d'Investigacions Biomèdiques August Pi i Sunyer",6,{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":150,"minAge":4,"maxAge":18,"enrollmentInfo":302,"targetDuration":304,"studyType":56,"phases":4,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":95},"100316365","diagnosis-and-management-of-intrauterine-growth-restriction-and-congenital-anomalies-100316365","NCT03398629","Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies","Diagnosis and Management of Intrauterine Growth Restriction, Structural Anomalies and Chromosomal Anomalies: A Prospective Cohort Study","Inclusion Criteria:\n\nAll pregnant women who present to Guangzhou Women and Children's Medical Center meeting one of the following prenatal diagnoses and neonates\u002Finfants who are diagnosed as one of the following anomalies will be invited to participate:\n\n1. Intrauterine growth restriction (IUGR)\n2. Structural anomaly\n3. Chromosomal anomaly\n\nExclusion Criteria:\n\n1. Pregnant women who don't agree to participate;\n2. Pregnant women delivering babies at other hospitals.\n3. Prenatally suspected anomalies that are not confirmed by postnatal diagnosis.",{"count":303,"type":21},10000,"20 Years","The purpose of this prospective cohort study is to build a large platform that includes clinical information (prenatal diagnosis and postnatal follow-up data) and biological specimen banks of fetuses\u002Finfants with IUGR or congenital anomalies, which provide vital support and research foundation for accurate diagnosis, precision treatment and meticulous management.",[29,307,308,235],"Fetal Anomaly","Chromosomal Anomalies","2019-06-03",{"date":311,"type":37},"2019-06-04",{"date":313,"type":37},"2019-05-01",{"date":315,"type":21},"2038-03-01",{"name":317,"class":44},"Guangzhou Women and Children's Medical Center"]